Ceftobiprole Noninferior to Daptomycin for Complicated Staph Infection
WEDNESDAY, Oct. 4, 2023 -- For patients with complicated Staphylococcus aureus bacteremia, ceftobiprole is noninferior to daptomycin for overall treatment success, according to a study published online Sept. 27 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2023 Category: Pharmaceuticals Source Type: news
Accord Healthcare Inc. Issues Nationwide Voluntary Recall of Daptomycin for Injection 500 mg/vial and Daptomycin for Injection 350 mg/vial Lot # R2200232 Due to Product Mix-Up
Accord Healthcare, Inc. is voluntarily recalling a single lot of Daptomycin for Injection 500 mg/vial, and Daptomycin for Injection 350 mg/vial product contained in cartons imprinted with lot # R2200232 Exp: 01/2025 to the consumer/user level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Conclusion: Oritavancin, used to support ED, is associated with lower costs compared with dalbavancin and reduced treatment duration relative to all comparators. Its use would support an ED approach in MRSA ABSSSI management. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news
A Once-Rejected Antibiotic Equals Standard for Complicated Staph Infections
(MedPage Today) -- WASHINGTON -- Investigational ceftobiprole was just as effective as daptomycin for bacterial bloodstream infections caused by Staphylococcus aureus bacteremia, the phase III ERADICATE trial demonstrated.
In the randomized... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 25, 2022 Category: Infectious Diseases Source Type: news
Merck Issues Voluntary Nationwide Recall of CUBICIN ® (Daptomycin for Injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is voluntarily recalling one lot of CUBICIN ® (daptomycin for injection) 500mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely to be initiated at a hospital or other monitored healthcare se (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 20, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Adjunctive Daptomycin Does Not Shorten the Duration of MSSA Bacteremia Compared to Standard-of-Care Therapy
A randomized, double-blind, placebo-controlled clinical trial of adults aged 18 years and older found that adjunctive daptomycin did not shorten the duration of methicillin-susceptible Staphylococcus aureus bacteremia compared to monotherapy with an antistaphylococcal beta-lactam antibiotic. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news
Infectious Disease Alert Updates
Sepsis Bundle Erodes Gains in Stewardship; Asymptomatic Transmission of COVID-19 in Households; When Is Hand Hygiene Personally Protective? Four different categories of antibiotic use were observed, including broad-spectrum antibiotics for community-acquired infection, broad-spectrum antibiotics for nosocomial infection/multidrug-resistant organisms, the use of anti-methicillin-resistant Staphylococcus aureus (MRSA) agents (such as vancomycin, daptomycin, linezolid, ceftaroline, etc.), as well as antibiotics for surgical prophylaxis. [...]a gap of up to 24 hours may occur before the physician picking up the case the next d...
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news
Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review
Staphylococcus aureus is one of the leading hospital-associated and community-associated pathogens, which has caused a global public health concern. The emergence of methicillin-resistant S. aureus (MRSA) along with the widespread use of different classes of antibiotics has become a significant therapeutic challenge. Antibiotic resistance is a disturbing problem that poses a threat to humans. Treatment options for S. aureus resistant to β-lactam antibiotics include glycopeptide antibiotic, cyclic lipopeptide antibiotic, cephalosporins and oxazolidinone antibiotic. The most representative types of these antibiotics are van...
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news
Cubicin RF (daptomycin) Injection
Title: Cubicin RF (daptomycin) InjectionCategory: MedicationsCreated: 7/8/2021 12:00:00 AMLast Editorial Review: 7/8/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 8, 2021 Category: Drugs & Pharmacology Source Type: news
Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial, Clinical Infectious Diseases
Conclusions Among patients with MSSA BSIs, the administration of adjunctive daptomycin therapy to standard-of-care treatment did not shorten the duration of bacteremia and should not be routine ly considered. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial, Clinical Infectious Diseases
Conclusions Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination preven ted microbiological failure and complicated bacteremia, but it was more often associated with adverse events. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news
Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections, Clinical Infectious Diseases 72: S68-S73
Conclusions Switching to daptomycin within 3 days of initial receipt of vancomycin is associated with lower 30-day mortality among patients with MRSA BSI. This benefit was not seen when the switch occurred later. Future studies should prospectively assess the benefit of early switching from vanco mycin to other anti-MRSA antibiotics. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news
FDA Rationale for Recognition Decision: Daptomycin
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection, Due to The Presence of Particulate
Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to the presence of particulate matter found in one single-dose vial manufactured b (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Antibiotic intercepts building blocks of the bacterial envelope
(University of Bonn) One of the last arrows in the quiver in the fight against dangerous bacteria is the reserve antibiotic daptomycin. It is used primarily when conventional drugs fail due to resistant bacteria. Although the antibiotic was developed around 30 years ago, its exact mode of action was previously unclear. Scientists at the University of Bonn have now deciphered the puzzle: Daptomycin blocks the integration of important building blocks into the cell wall of the pathogens. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 20, 2020 Category: Infectious Diseases Source Type: news
